Horizon Therapeutics announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease patients with DON, the majority of whom had not previously responded to other treatments. This analysis summarizes real-world experience of people living with TED and DON who were treated with TEPEZZA between January 2020 and September 2022. During this period, 24 patients were identified from literature and the author’s clinical experience with most receiving treatment with oral or intravenous steroids, surgery and/or radiation prior to TEPEZZA. After TEPEZZA treatment, meaningful improvement was observed in visual acuity in eyes with DON; proptosis; diplopia; and Clinical Activity Score. Reported adverse events were consistent with TEPEZZA clinical trials and included fatigue, dysgeusia, hearing issues, nausea, hyperglycemia and muscle spasms.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HZNP:
- Horizon Therapeutics reports Q4 EPS $1.21, consensus $1.09
- Horizon updates Uplizna data from analyses of the N-MOmentum trial for NMOSD
- George Soros Makes Major Changes to His Stock Positions
- Horizon Pharma put volume heavy and directionally bearish
- Horizon Pharma call volume above normal and directionally bullish
